

CURRICULUM VITAE

Informazioni personali

<i>Nome e Cognome</i>	Matteo Parma
<i>Data di nascita</i>	10/7/68
<i>Qualifica</i>	Dir Medico 1° Livello
<i>Amministrazione</i>	H.S. Gerardo
<i>Incarico attuale</i>	Dir. Medico Clinica Ematologica
<i>Numero telefonico ufficio</i>	039-2332392
<i>Indirizzo e-mail istituzionale</i>	m.parma@hsgerardo.org

Titoli di studio e professionali ed esperienze lavorative

<i>Titolo di studio</i>	Laure in Medicina e Chirurgia
<i>Specializzazione</i>	Ematologia
<i>Esperienze professionali (incarichi ricoperti)</i>	1999 Divisione di Medicina, Ospedale di S. Giovanni Bianco (BG) 2000 Divisione di Medicina I, Ospedale di Treviglio (BG) 2001 Divisione di Ematologia, Ospedale S. Gerardo, Monza
<i>Capacità linguistiche</i>	Inglese
<i>Capacità nell'uso delle tecnologie</i>	Discreta
<i>Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazioni a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)</i>	Pubblicazioni scientifiche negli ultimi 5 anni
	1. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, Agostoni V, Parma M, Ponzoni M, Bertilaccio MT, Ghia P, Biondi A, Dotti G, Biagi E. Blood. 2011 May 5;117(18):4736-45. Epub 2011 Mar 15.
	2. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C. Leukemia. 2010

	<p>Aug;24(8):1445-9. Epub 2010 Jun 3.</p> <hr/> <p>3. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, André V, Todisco E, Rahal D, Migliavacca M, Longoni D, Solinas G, Villa A, Berti E, Mina PD, Parma M, Allavena P, Biagi E, Rovelli A, Biondi A, D'Amico G. Transplantation. 2009 Dec 15;88(11):1261-72.</p> <hr/> <p>4. GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy. Gaipa G, Tilenni M, Straino S, Burba I, Zaccagnini G, Belotti D, Biagi E, Valentini M, Perseghin P, Parma M, Campi CD, Biondi A, Capogrossi MC, Pompilio G, Pesce M. J Cell Mol Med. 2010 Jun;14(6B):1619-34. Epub 2009 Jul 20.</p> <hr/> <p>5. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P. Transfus Apher Sci. 2009 Aug;41(1):33-7. Epub 2009 Jun 18.</p> <hr/> <p>6. A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript. Parma M, Colnaghi F, Colombo A, Elli E, Rossi F, Gaipa G, Rossi V, Casaroli I, Biondi A, Pogliani EM. Leuk Res. 2009 Nov;33(11):e175-7. Epub 2009 May 23. No abstract available.</p> <hr/> <p>7. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Di Biaso I, Di Maio L, Bugarin C, Gaipa G, Dander E, Balduzzi A, Parma M, D'Amico G, Perseghin P, Biondi A, Biagi E. Transplantation. 2009 May 15;87(9):1422-5.</p> <hr/> <p>8. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Blood. 2009 Apr 2;113(14):3375-82. Epub 2008 Dec 8.</p> <hr/> <p>9. Ceftriaxone/Amikacin vs Ceftazidime/Amikacin as Empirical Therapy for Fever in Patients with Haematological Malignancy and Severe Granulocytopenia: Clinical and Economic Outcomes. Rossini F, Pioltelli P, Bolis S, Borin L, Casaroli I, Lanzi E, Maffè P, Parma M, Tripputi P, Pogliani EM. Clin Drug Investig. 1998;15(5):425-33.</p> <hr/> <p>10. Extracorporeal photochemotherapy is</p>
--	--

	<p>accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A. Transplantation. 2007 Jul 15;84(1):31-9.</p>
	<p>11. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A. Haematologica. 2007 Jul;92(7):952-9.</p>
	<p>12. Successful treatment with T-depleted autologous peripheral blood stem cell transplantation of refractory chronic autoimmune thrombocytopenic purpura. Elli E, Parma M, Perseghin P, Dassi M, Terruzzi E, Belotti D, Pioltelli P, Pogliani EM. Haematologica. 2007 Jan;92(1):e7-8.</p>
	<p>13. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Rossini F, Terruzzi E, Cammarota S, Morini F, Fumagalli M, Verga L, Elli E, Verga M, Miccolis I, Parma M, Pogliani EM. Transpl Infect Dis. 2005 Sep-Dec;7(3-4):122-5.</p>
	<p>14. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Perseghin P, Gambacorti-Passerini C, Tornaghi L, Dassi M, Pioltelli P, Parma M, Colnaghi F, Giudici G, Elli E, Fumagalli M, Ponchio L, Biondi A, Pogliani EM. Transfusion. 2005 Jul;45(7):1214-20.</p>
	<p>15. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. Rossini F, Terruzzi E, Verga L, Larocca A, Marinoni S, Miccolis I, Giltri G, Isella M, Parma M, Pogliani EM. Support Care Cancer. 2005 Jun;13(6):387-92. Epub 2004 Dec 15.</p>